Composition
Active ingredient: Â
- calcium hopanthenate (calcium salt of hopanthenic acid) – 500.0 mg;
excipients: Â
- magnesium hydroxycarbonate – 93.6 mg;
- talc-18.6 mg;
- calcium stearate-6.2 mg;
- methylcellulose-1.6 mg
Pharmacological action
Pharmacodynamics pectrum of hopantenic acid is associated with the presence of gamma-aminobutyric acid (GABA) in its structure. The mechanism of action is due to the direct effect of the drug on the GABAB-receptor-channel complex. Hopantenic acid has a nootropic and anticonvulsant effect. The drug increases the brain’s resistance to hypoxia and toxic substances, stimulates anabolic processes in neurons, combines a moderate sedative effect with a mild stimulating effect, reduces motor excitability, activates mental and physical performance. Improves GABA metabolism during chronic alcohol intoxication and after ethanol withdrawal. Hopantenic acid is able to inhibit the acetylation reactions involved in the mechanisms of inactivation of procaine (novocaine) and sulfonamides, thereby prolonging the action of the latter. Causes inhibition of pathologically elevated cystic reflex and detrusor tone. Pharmacokinetic AHopantenic acid is rapidly absorbed from the gastrointestinal tract, penetrates the blood-brain barrier, and the highest concentrations are created in the liver, kidneys, stomach wall, and skin. The drug is not metabolized and is excreted unchanged within 48 hours: 67.5% of the dose taken – in the urine,28.5% – in the feces.
Indications
- Cognitive disorders in organic brain lesions, including the consequences of neuroinfections, traumatic brain injury and neurotic disorders;
- extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system in combination with therapy;
- as a corrector in side effects antipsychotics, with neuroleptic extrapyramidal syndrome (hyperkinetic and akinetic), in the complex therapy for cerebral organic insufficiency in schizophrenia patients;
- epilepsy with slowing of mental processes in complex therapy with anticonvulsants;
- psycho-emotional overload, reduced mental and physical performance, to improve concentration and memory;
- neurogenic disorders of urination (Pollakiuria, urgency imperative, imperative urinary incontinence, enuresis);
- children with developmental delay (mental, language, and motor or combinations thereof), including on the background of suffering perinatal encephalopathy in children with different forms of cerebral palsy;
- children with hyperkinetic disorder (hyperactivity disorder with attention deficit);
- children with neurotic-like States (tics, stuttering, mostly in the form of clonic).
Use during pregnancy and lactation
It is not recommended to use the drug during pregnancy and lactation due to the lack of experience of clinical use in this category of patients.
Contraindications
- Hypersensitivity to hopantenic acid and other components of the drug;
- acute severe kidney diseases;
- pregnancy;
- breast-feeding;
- children under 3 years of age.
Side effects
Classification of the frequency of side effects according to the recommendations of the World Health Organization (WHO): very common ≥1/10; common ≥1/100 to <1/10; uncommon ≥1/1000 to <1/100; rare ≥1/10000 to <1/1000;very rare Immune system disorders: very rare: allergic reactions (rhinitis, conjunctivitis, allergic skin reactions). Nervous system disorders: very rare: hyperexcitation, headache, dizziness, noise in the head. Mental disorders: very rare: lethargy, lethargy, sleep disturbance, drowsiness. In case of disorders of the immune system, the drug is canceled. In other cases, reduce the dose of the drug.
Interaction
Prolongs the action of barbiturates, enhances the effect of anticonvulsants, prevents side effects of phenobarbital, carbamazepine, neuroleptics. The effect of hopanthenic acid is enhanced in combination with glycine, ethidronic acid. Potentiates the action of local anesthetics (procaine).
How to take, course of use and dosage
Inside,15-30 minutes after eating. A single dose for adults is usually 250-1000 mg, for children-250-500 mg; a daily dose for adults – 1500-3000 mg, for children-750-3000 mg. The course of treatment is from 1 to 4 months, in some cases up to 6 months. After 3-6 months, it is possible to conduct a second course of treatment. For cognitive disorders in organic brain lesions, including the consequences of neuroinfections, traumatic brain injuries, and neurotic disorders:  250 mg 3-4 times a day. For extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system in combination with ongoing therapy:  in a dose of 500 to 3000 mg per day. The course of treatment is up to 4 months or more. As a corrector for the side effects of neuroleptics, for neuroleptic extrapyramidal syndrome (hyperkinetic and akinetic), as part of complex therapy for cerebral organic insufficiency in patients with schizophrenia:  adults – at a dose of 500 to 1000 mg 3 times a day; children-at a dose of 250 to 500 mg 3-4 times a day. The course of treatment is 1-3 months. In epilepsy with slowing of mental processes in complex therapy with anticonvulsants:  adults – at a dose of 500 to 1000 mg 3 times a day; children-at a dose of 250 to 500 mg 3-4 times a day. The course of treatment is up to 6 months. With psychoemotional overload, reduced mental and physical performance, to improve concentration and memorization:  250 mg 3 times a day. For neurogenic urination disorders:  adults – at a dose of 500 to 1000 mg 2-3 times a day; children-at a dose of 250 to 500 mg 3 times a day (the daily dose is 25-50 mg / kg). The course of treatment is 1-3 months. Children with various pathologies of the nervous system, depending on their age, are recommended to take the drug up to 3000 mg per day. Tactics of prescribing the drug: increasing the dose for 7-12 days, taking the maximum dose for 15-40 days and gradually reducing the dose until the drug is discontinued for 7-8 days. The break between course doses of the drug, as for any other nootropic agent, is from 1 to 3 months. Children with developmental delays:  500 mg 3-4 times a day. The course of treatment is 2-3 months. Children with hyperactivity syndrome with attention deficit disorder depending on body weight are prescribed the drug at an average therapeutic dose of 30 mg / kg per day, morning and afternoon. The optimal dose is determined for each patient individually by selecting with a gradual increase in the dose during the first 5-7 days. The course of treatment is 3-4 months. Children with neurosis-like conditions (tics, stuttering, mainly in the clonic form):  in a dose of 250 to 500 mg 3-6 times a day. The course of treatment is 1-4 months. Taking into account the nootropic effect of the drug, it is preferably taken in the morning and afternoon hours (up to 17 hours).
Overdose
In case of overdose, there is an increase in the severity of dose-dependent side effects. Symptoms: Sleep disturbance or drowsiness, noise in the head. Treatment: Activated charcoal, gastric lavage, symptomatic therapy.
Special instructions
In conditions of long-term treatment, simultaneous use of the drug with other nootropic and stimulating agents is not recommended. In case of development of undesirable reactions, such as allergic rhinitis, conjunctivitis, allergic skin reactions, the drug should be discontinued. In case of adverse events from the central nervous system, it is necessary to reduce the dose of the drug. Taking into account the nootropic effect of the drug, it is preferably taken in the morning and afternoon hours (up to 17 hours).
Storage conditions
Store in a dark place at a temperature not exceeding 25 °C. Keep out of reach of children.
Shelf
life is 2 years.
Active ingredient
Hopanthenic acid
Conditions of release from pharmacies
By prescription
Dosage form
Tablets
Best price for Gopantenic acid pills 250mg, 50pcs in our online pharmacy!
Side effects of Gopantenic acid pills 250mg, 50pcs.
Reviews
There are no reviews yet